Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
Jorge Enrique Machado-AlbaManuel Enrique Machado-DuqueAndrés Gaviria-MendozaJuan Manuel ReyesNatalia Castaño GamboaPublished in: Clinical rheumatology (2020)
In the face of a first failure of cDMARD, bDMARDs are frequently added. A high frequency of patients do not persist treatment during the first year of follow-up. The pharmacological treatment is the most representative cause of healthcare costs. Key Points • Rheumatoid arthritis is a disease with a high burden of comorbidities, complications, and worse health-related quality of life and is associated with elevated healthcare costs. • The biological disease-modifying antirheumatic drugs or tofacitinib medications are indicated for those with significant progression of the disease and when there is a need for alternatives to achieve low levels of activity and remission. • Patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs or tofacitinib represent a significant economic burden to the health system, especially in the costs derived from pharmacological treatment.
Keyphrases
- rheumatoid arthritis
- healthcare
- disease activity
- high frequency
- end stage renal disease
- transcranial magnetic stimulation
- chronic kidney disease
- rheumatoid arthritis patients
- social media
- prognostic factors
- systemic lupus erythematosus
- cross sectional
- systemic sclerosis
- combination therapy
- health information
- drug induced
- smoking cessation